Department of Dermatology, Indiana University School of Medicine, Indianapolis, Indiana.
Deparment of Dermatology, University of Health Sciences, Ankara Numune Training and Research Hospital, Ankara, Turkey.
Dermatol Ther. 2018 Mar;31(2):e12586. doi: 10.1111/dth.12586. Epub 2018 Jan 9.
Several chemotherapy agents have shown efficacy in the treatment of mycosis fungoides (MF). In the literature, there is limited data on the use of single agent etoposide for MF. We aimed to retrospectively review our experience with single agent etoposide in the treatment of advanced-stage or refractory early-stage MF with focus on analyzing its efficacy and safety. We included 13 MF patients who were treated with single agent etoposide. Patients were identified through the Cutaneous T Cell Lymphoma Database of Indiana University that involves patients treated from 2006 to 2016. Overall nine patients (69%) responded to treatment. No complete response was identified. Median time to response was 12.5 weeks (range: 6-25.4). Median duration of response was 43 weeks (range: 5-60) and median time to treatment failure was 31.3 weeks (range: 12.4-230). Hematological toxicity was observed in eight patients including two patients with grade 4 neutropenia and/or lymphopenia leading to sepsis. Higher doses of etoposide were significantly correlated with higher grades of anemia, neutropenia or lymphopenia (p < .05). Our study demonstrates that etoposide is an effective treatment for MF and may be considered in selected patients with progressive MF who have failed other treatments.
几种化疗药物已被证明在蕈样肉芽肿（MF）的治疗中有效。在文献中，关于单药依托泊苷治疗 MF 的数据有限。我们旨在回顾性分析单药依托泊苷治疗晚期或难治性早期 MF 的经验，重点分析其疗效和安全性。我们纳入了 13 例接受单药依托泊苷治疗的 MF 患者。这些患者是通过印第安纳大学皮肤 T 细胞淋巴瘤数据库确定的，这些患者的治疗时间为 2006 年至 2016 年。总体而言，有 9 名患者（69%）对治疗有反应。未发现完全缓解。反应时间的中位数为 12.5 周（范围：6-25.4）。反应持续时间的中位数为 43 周（范围：5-60），治疗失败的时间中位数为 31.3 周（范围：12.4-230）。有 8 名患者出现血液学毒性，包括 2 名中性粒细胞减少症和/或淋巴细胞减少症 4 级患者，导致败血症。依托泊苷的较高剂量与贫血、中性粒细胞减少症或淋巴细胞减少症的较高等级显著相关（p<.05）。我们的研究表明，依托泊苷是治疗 MF 的有效药物，对于其他治疗失败的进展性 MF 患者，可考虑使用该药。
